FDA asks industry for help with approved process
This article was originally published in Clinica
The US FDA's Center for Devices and Radiological Health (CDRH) has asked for a January 4 meeting with industry to discuss how the agency should meet the "least burdensome" requirement contained in the FDA Modernization Act of 1997 (FDAMA).
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.